Latest Pharma and Biotech News
Biotechnology
20 May 2026 Privately-held UK based AMR Bio has announced its launch as a clinical phase biotechnology company focused on one of the most urgent public health challenges: preventing infection in an era where antibiotics are becoming less effective.
Today's issue
Refine search
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on its proposed Rare Disease Therapies Framework designed to accelerate development and approval of treatments for rare and ultra-rare conditions. 21 May 2026
Biotechnology
Scenic Biotech has progressed enormously since it was founded in 2017 as a spin-out from the Netherlands Cancer Institute and Oxford University by Sebastian Nijman and Thijn Brummelkamp. 20 May 2026
Pharmaceutical
American States are rolling out complex drug price-setting efforts - but there is no evidence yet that patients are or will save money at the pharmacy counter, according to trade group Pharmaceutical Research Manufacturers of America (PhRMA). 20 May 2026
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced a planned leadership transition, appointing Maria Paola Chiesi as chair of its board of directors, succeeding Alessandro Chiesi, who will become vice chair. 20 May 2026
Biotechnology
A new national framework designed to strengthen the delivery of advanced therapy clinical trials across the UK has been launched by the Advanced Therapy Treatment Centre (ATTC) network, as the country seeks to reinforce its position in the fast-growing cell and gene therapy sector. 20 May 2026
Pharmaceutical
Remepy, a New York firm developing a new category of therapy by combining pharmaceuticals with targeted digital interventions through its Hybrid Drug platform today announced that the Phase IIa clinical trial of Hybridopa, a new Hybrid Drug for Parkinson’s disease, met its primary endpoint. 20 May 2026
Pharmaceutical
US pharma giant Pfizer today announced data from its Phase II study evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of Prevenar 20 at months 2, 4, 6 and 12-15. 20 May 2026
Biosimilars
Olayan Financing Company (OFC) has made a minority equity investment in Jordan-headquartered MS Pharma, a leading pharma player in the Middle East North Africa (MENA) region that specializes in the development, production and distribution of a broad portfolio of generic and biologic therapies. 20 May 2026
Biotechnology
Texas, USA-based clinical-stage biotech Oorja Bio has announced the company’s launch and $30 million in Series A financing from its founding investor, Westlake BioPartners. 20 May 2026
Pharmaceutical
Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work. 20 May 2026
Biotechnology
US allogeneic NK cell therapies developer Artiva Biotherapeutics announced the appointment of Dr Diego Miralles as president and head of research and development. 20 May 2026
Biotechnology
Privately-held UK based AMR Bio has announced its launch as a clinical phase biotechnology company focused on one of the most urgent public health challenges: preventing infection in an era where antibiotics are becoming less effective. 20 May 2026
Pharmaceutical
The US Supreme Court has declined to hear legal challenges from several major drugmakers seeking to block Medicare drug price negotiations under the Inflation Reduction Act (IRA), dealing another setback to the industry’s effort to overturn the Biden-era law. 20 May 2026
Pharmaceutical
French drugmaker Ipsen has reported that Dysport (abobotulinumtoxinA) delivered longer-lasting symptom control than AbbVie’s Botox (onabotulinumtoxinA) in a Phase IV study of adults with upper limb spasticity, while maintaining a comparable safety profile. 20 May 2026
Pharmaceutical
The World Health Organization (WHO) has declared the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern (PHEIC), citing the risk of cross-border spread and the need for coordinated international action. 20 May 2026
Biotechnology
Canadian biotech InMed Pharmaceuticals is set to merge with privately held Mentari Therapeutics in an all-stock reverse merger that will create a Nasdaq-listed company focused on next-generation migraine prevention therapies. 20 May 2026
Pharmaceutical
Japan’s largest drugmaker Takeda yesterday announced that a jury in the US District Court for the District of Massachusetts returned a verdict against Takeda in the Amitiza (lubiprostone) antitrust litigation and awarded plaintiff $885 million in damages, a figure that could be roughly tripled under antitrust law. 20 May 2026
Biotechnology
US biotech major Amgen has announced the retirement of Peter Griffith, who has served as the company’s executive vice president and chief financial officer since 2020. 20 May 2026
Pharmaceutical
Torii Pharmaceutical, a wholly owned subsidiary of Japan’s Shionogi, today announced positive interim analysis results (data cutoff: March 2026) of Phase III trial in infant patients with atopic dermatitis in Japan for tapinarof cream 0.5%, an Aryl hydrocarbon Receptor (AhR) modulating agent. 19 May 2026
Pharmaceutical
Shares of US precision medicines company Relay Therapeutics were up 11.3% at $12.10 in pre-market activity today, after it announced highly encouraging initial clinical data from the Phase ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition. 19 May 2026
All news
Biotechnology
San Diego, USA-based precision oncology company Erasca, which is developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, yesterday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck & Co. 12 May 2026
Biotechnology
US biotech Inhibrx Biosciences has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing the drug significantly improved response rates when added to Merck & Co’s Keytruda (pembrolizumab) in first-line head and neck cancer. 12 May 2026
Biotechnology
US biotech MacroGenics has agreed to sell its GMP manufacturing operations to Taiwanese contract manufacturer Bora Pharmaceuticals for $122.5 million upfront, as the oncology-focused company continues a broader effort to slim down operations and preserve cash for its drug pipeline. 12 May 2026
Biotechnology
AOP Health, an Austrian enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership with VRG Therapeutics, an AI-driven developer for miniproteins based in Budapest, Hungary. 12 May 2026
Pharmaceutical
The Wall Street Journal Editorial Board is once again raising concerns about the USA’s federal 340B drug pricing program – this time questioning whether the program is benefiting patients at all. 12 May 2026
Biotechnology
German biotech Exciva GmbH, which is developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the appointment of Mark Altmeyer as chairman of its board of directors. 12 May 2026
Pharmaceutical
US drug developer Cytokinetics today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock. 11 May 2026
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated safety advice to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on a similar product, dutasteride. 11 May 2026
Pharmaceutical
Spanish drugmaker Almirall has reported first-quarter 2026 results in line with expectations, driven by continued strong momentum in its European dermatology business and biologics portfolio. 11 May 2026
Pharmaceutical
UK pharma major GSK’s majority-owned HIV specialist ViiV Healthcare today announced that the European Medicines Agency (EMA) has validated the company’s marketing application seeking approval to extend the use of Dovato (dolutegravir/lamivudine (DTG/3TC)) to younger age groups. 11 May 2026
Biotechnology
Daiichi Sankyo today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen ($14.64 billion) in oncology revenue by 2030 and be a global top five oncology company by 2035. 11 May 2026
Biotechnology
San Diego-based Capricor Therapeutics, a biotech developing cell and exosome-based therapeutics for rare diseases, has filed a lawsuit Japanese pharma against Nippon Shinyaku and its US subsidiary, NS Pharma. 11 May 2026
Pharmaceutical
This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s Phase III CARDIO-TTRansform trial was presented. 11 May 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Pharmaceutical
Japanese drugmaker Nxera Pharma has entered into a license agreement with a newly established company (NewCo) to advance a specific GPCR-targeted program owned by Nxera. Nxera shares rose 6.4% to 1,242 yen on the news. 11 May 2026
Pharmaceutical
Europe risks losing its position in innovative medicines as China and the USA sharpen their industrial strategies and investment incentives, according to the Dutch trade body Vereniging Innovatieve Geneesmiddelen (VIG). 11 May 2026
Pharmaceutical
For the first time, Swedish pharma trade group Lif launched its own program track at Vitalis. Together with the Swedish Medical Products Agency, SweTrial and Swedish Medtech, the focus was on how Sweden can strengthen its position as an attractive clinical trial country. 11 May 2026
Biotechnology
US clinical-stage biotech Odyssey Therapeutics has raised around $304 million through an upsized initial public offering and concurrent private placement, giving the autoimmune specialist a stronger-than-expected return to public markets. 11 May 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze